Tag: SGN-LIV1A
Seagen Presents Broad Portfolio of Innovative Immuno-Oncology Data – Featuring Sugar-Engineered...
During the upcoming 35th annual meeting of the Society for Immunotherapy of Cancer’s (SITC) being held November 9-14, 2020, Seagen (previously known as Seattle...
Updated Phase I Data for Ladiratuzumab Vedotin in Patients with Triple...
Data from an ongoing phase I clinical trial evaluating ladiratuzumab vedotin, also known as SGN-LIV1A, in patients with metastatic triple negative breast cancer presented...
Combination of SGN-LIV1A + Pembrolizumab to be Investigated as First Line...
Breast cancer is a cancer which forms in breast tissue. Metastatic breast cancer occurs when the cancer has spread to other parts of the...
Clinical Collaboration to Expand the Therapeutic Evaluation of SGN-LIV1A in Triple...
Seattle Genetics has signed a clinical collaboration agreement with Genentech, a member of the Roche Group, for the evaluation of its investigational antibody-drug conjugate...
SGN-LIV1A Monotherapy Data Show 37% ORR in Heavily Pretreated Triple Negative...
Data from an ongoing phase I clinical trial evaluating SGN-LIV1A for patients with metastatic breast cancer (MBC), with particular focus on metastatic triple-negative breast...
SGN-LIV1A Demonstrates Antitumor Activity and Well-Tolerated Safety Profile in Patients with...
Data presented today from an ongoing phase I clinical trial evaluating SGN-LIV1A, an antibody-drug conjugate or ADC being developed by Seattle Genetics for the...
Phase I Trial of SGN-LIV1A Initiated in LIV-1-Positive Metastatic Breast Cancer
A new phase I clinical trial was initiated late October 2013 to evaluate SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer. SGN-LIV1A is based...
Phase I Trial of Seattle Genetics’ SGN-LIV1A for Patients with LIV-1-Positive...
A new phase 1 clinical trial evaluating SGN-LIV1A for patients with LIV-1-positive metastatic breast cancer has started. SGN-LIV1A utilizes Seattle Genetics’ industry-leading antibody-drug conjugate...
